No matches
Pulmonology

ERS 2026 | Breaking Silos Between Asthma and CRSwNP: Loss of Smell as a Marker of Unified Airway Disease

Join experts Roland Buhl, Joaquim Mullol, and Giselle Mosnaim as they discuss the role of type 2 inflammation across the unified airway, with a focus on the amplified burden and the difficulty controlling inflammation when asthma and CRSwNP coexist.
Roland Buhl
Giselle Mosnaim
Joaquim Mullol
MD, PhD
Roland Buhl +2 more

Related resources

Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

expert video
CRSwNP Interactive Patient Case Tool

CRSwNP Interactive Patient Case Tool

interactivity
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

expert video
On-Treatment Asthma Remission Infographic

On-Treatment Asthma Remission Infographic

Infographic
AFRS Disease Burden Infographic

AFRS Disease Burden Infographic

Infographic
The Compounded Burden of CRSwNP and Asthma

The Compounded Burden of CRSwNP and Asthma

interactivity
Corticosteroids in Asthma Management

Corticosteroids in Asthma Management

Infographic
On-Treatment Asthma Remission Infographic

On-Treatment Asthma Remission Infographic

interactivity
ADVENT on Air: OCS in CRSwNP Podcast

ADVENT on Air: OCS in CRSwNP Podcast

Podcast
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Infographic
ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

expert video
ERS 2025 | The Knowns and Unknowns in the COPD Landscape

ERS 2025 | The Knowns and Unknowns in the COPD Landscape

expert video
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Podcast
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

Podcast
Understanding the Clinical Impact of Mucus Plugs in COPD

Understanding the Clinical Impact of Mucus Plugs in COPD

Infographic
ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

Podcast
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Infographic
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

videoanimation
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

videoanimation
Exploring the Mechanisms of FeNO Production in the Lungs

Exploring the Mechanisms of FeNO Production in the Lungs

videoanimation
Mechanisms of Production and Clinical Impact of IgE

Mechanisms of Production and Clinical Impact of IgE

videoanimation
Pathways Driving Chronic Airway Remodeling in Asthma

Pathways Driving Chronic Airway Remodeling in Asthma

videoanimation
How Type 2 Inflammation Drives Eosinophils in Asthma

How Type 2 Inflammation Drives Eosinophils in Asthma

videoanimation
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Eosinophils: A Biomarker in COPD

Eosinophils: A Biomarker in COPD

Infographic
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

interactivity
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP

Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP

videoanimation
Assessment of Smell Loss in CRSwNP Interactive Infographic

Assessment of Smell Loss in CRSwNP Interactive Infographic

interactivity
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
Worsening Disease Results in a Vicious Cycle of COPD

Worsening Disease Results in a Vicious Cycle of COPD

interactivity
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
Partnering With Patients for Clinical Decision-Making in CRSwNP

Partnering With Patients for Clinical Decision-Making in CRSwNP

expert video
The Compounded Burden of CRSwNP and Asthma

The Compounded Burden of CRSwNP and Asthma

Infographic
Dynamic Eosinophils: Decoding Variability in COPD

Dynamic Eosinophils: Decoding Variability in COPD

interactivity
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma

ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma

expert video

Learning objectives

  • Describe the pathophysiological mechanisms of type 2 inflammation across the Unified Airway
  • Explain the diagnostic and endotypic relevance of smell loss, including its prevalence and significant impact on patient burden
  • Recognize the challenges in achieving disease control and the increased steroid burden in patients with severe CRSwNP and asthma
  • Evaluate the current evidence of biologic therapies for improving olfactory function and overall disease control in patients with CRSwNP

Description

Explore the available clinical data supporting the impact of current therapies on olfaction, lung function, and disease control.

Tags
Pathophysiologyloss of smellburden of diseasebiologics
MAT-GLB-2605767 - 1.0 -11/2026

About these experts

Pulmonology
MD, PhD

Roland Buhl

Professor of Medicine | Johannes Gutenberg University of Mainz, Germany | Head of the Pulmonary Department | Mainz University Hospital, Germany

Rhinology
MD, MS, FAAAAI, FACAAI

Giselle Mosnaim

Giselle Mosnaim is a board-certified allergist and immunologist at Endeavor Health and Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine. An internationally recognized expert in asthma and allergic diseases, her clinical and research interests focus on severe and uncontrolled asthma, digital health, and improving patient outcomes through innovative, evidence-based care.

Rhinology
MD, PhD

Joaquim Mullol

Director of the Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology | Hospital Clinic, Barcelona, Spain; Professor of Research and Head of the Laboratory of Clinical and Experimental Respiratory Immunoallergy | August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain | Head of Research Group at Biomedical Research Network on Respiratory Diseases (CIBERES) | Carlos III Institute of Health, Barcelona, Spain

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region